A Study of LY3041658 in Adults With Hidradenitis Suppurativa

• Status: Recruiting
• Trial end date: 2022-11-02
• Target enrollment: 0
• Participant gender: All

Summary

The reason for this study is to see if the study drug LY3041658 is effective in participants with moderate-to-severe hidradenitis suppurativa (HS).

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Eli Lilly and Company

Criteria

Inclusion Criteria:

• Have a diagnosis of HS for at least 6 months

• Have HS lesions in at least 2 different anatomic areas

• Have inadequate response or intolerance to a 28 day course of oral antibiotics

• Have a total count of abscesses and inflammatory nodules greater than or equal to 4

• Agree to use a topical antiseptic daily

• Agree to stop using topical antibiotics during the study. In certain cases, oral antibiotics will be allowed

Exclusion Criteria:

• Have more than 20 draining fistulae

• Have received any biologic medication (adalimumab, etc.) for the treatment of HS

• Plan to use oral opioids for HS-related pain during the study

• Uncontrolled depression or suicidal thoughts